Gsk (GSK) Other Non-Current Assets (2009 - 2026)
Gsk (GSK) posted quarterly Other Non-Current Assets of $3.6 billion for Q2 2026, up 33.48% year-over-year from $2.7 billion in Q2 2025, and up 11.83% quarter-over-quarter from $3.2 billion in Q1 2026.
Gsk (GSK) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Gsk's Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $3.6 billion for Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 33.48% year-over-year to $3.6 billion; the TTM figure through Jun 2026 stood at $3.6 billion (up 33.48% YoY), while the FY2025 annual figure was $2.8 billion, up 14.09% from the prior year.
- Other Non-Current Assets for Q2 2026 stood at $3.6 billion, up from $3.2 billion in the prior quarter.
- The five-year high for Other Non-Current Assets was $3.6 billion in Q2 2026, with the low at $32.2 million in Q1 2022.
- The 5-year median for Other Non-Current Assets is $2.2 billion (2022), against an average of $2.2 billion.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets tumbled 97.64% in 2022, then jumped 5546.5% in 2023.
- Gsk's Other Non-Current Assets stood at $1.4 billion in 2022, then soared by 40.38% to $2.0 billion in 2023, then climbed by 26.78% to $2.5 billion in 2024, then gained by 14.63% to $2.9 billion in 2025, then increased by 24.58% to $3.6 billion in 2026.
- Business Quant data shows GSK's Other Non-Current Assets at $3.6 billion in Q2 2026, $3.2 billion in Q1 2026, and $2.9 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.56 Bn |
| Mar 31, 2026 | 3.18 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Sep 30, 2025 | 2.88 Bn |
| Jun 30, 2025 | 2.67 Bn |
| Mar 31, 2025 | 2.55 Bn |
| Dec 31, 2024 | 2.49 Bn |
| Sep 30, 2024 | 2.52 Bn |
| Jun 30, 2024 | 2.18 Bn |
| Mar 31, 2024 | 2.10 Bn |
| Dec 31, 2023 | 1.97 Bn |
| Sep 30, 2023 | 1.45 Bn |
| Jun 30, 2023 | 1.75 Bn |
| Mar 31, 2023 | 1.82 Bn |
| Dec 31, 2022 | 1.40 Bn |
| Sep 30, 2022 | 1.38 Bn |
| Jun 30, 2022 | 2.19 Bn |
| Mar 31, 2022 | 32.20 Mn |
| Dec 31, 2021 | 2.26 Bn |
| Sep 30, 2021 | 1.72 Bn |